> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Joint Panel to Review Nektar Back Pain Drug
- URL: https://www.fdaweb.com/joint-panel-to-review-nektar-back-pain-drug/
- Published: 2019-12-06T12:00:00.000Z
- Updated: 2026-09-14T15:55:46.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5145669

*Federal Register* notice: FDA has announced a 1/14/2020 Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee joint meeting. The committees will discuss a Nektar Therapeutics NDA for oxycodegol, a new molecular entity full mu-opioid receptor agonist for managing chronic low back pain in adult patients with pain severe enough to require daily, around-the- clock, long-term opioid treatment and for which alternative treatment options are inadequate. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2019-12-06/pdf/2019-26338.pdf?ref=fdaweb.com).